Calcium gluconate 500 mg 50 tablets

Calcium gluconate is indicated for adults and children from 3 years of age:

• diseases accompanied by hypocalcemia, increased permeability of cell membranes (including blood vessels), and impaired conduction of nerve impulses in muscle tissue;

• hypoparathyroidism (latent tetany, osteoporosis), vitamin D metabolism disorders: rickets (spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic renal failure;

• increased demand for calcium ions (pregnancy, breastfeeding, period of accelerated growth), insufficient calcium ion content in food, impaired calcium metabolism (in the postmenopausal period);

• increased excretion of calcium ions (prolonged bed rest, chronic diarrhea, secondary hypocalcemia due to prolonged use of diuretics and antiepileptic drugs, glucocorticoids);

• poisoning with magnesium salts, oxalic and hydrofluoric acids and their soluble salts (when interacting with calcium gluconate, insoluble and non-toxic calcium oxalate and calcium fluoride are formed);

• hyperkalemic form of paroxysmal myoplegia.

Orally. Before meals or 1-1.5 hours after meals (with milk). The tablet must be crushed before use.
Dosages are determined individually by the attending physician based on the clinical picture.
Hypoparathyroidism (latent tetany, osteoporosis)
Adults
1000-3000 mg (2-6 tablets) 2-3 times a day;
Children
3-4 years - 1000 mg (2 tablets); 5-6 years - 1000-1500 mg (2-3 tablets); 7-9 years - 1500-2000 mg (3-4 tablets); 10-14 years - 2000-3000 mg (4-6 tablets); frequency of administration - 2-3 times a day.
Vitamin D metabolism disorders; rickets (spasmophilia, osteomalacia), hyperphosphatemia in patients with chronic kidney disease
Adults
1000-3000 mg (2-6 tablets) 2-3 times a day.
Children
3-4 years - 1000 mg (2 tablets); 5-6 years - 1000-1500 mg (2-3 tablets); 7-9 years - 1500-2000 mg (3-4 tablets); 10-14 years - 2000-3000 mg (4-6 tablets); frequency of administration - 2-3 times a day.
Increased calcium requirement (pregnancy, lactation, period of rapid growth), insufficient calcium content in food, impaired calcium metabolism
Adults
1000-3000 mg (2-6 tablets) 2-3 times a day.
Children
3-4 years - 1000 mg (2 tablets); 5-6 years - 1000-1500 mg (2-3 tablets); 7-9 years - 1500-2000 mg (3-4 tablets); 10-14 years - 2000-3000 mg (4-6 tablets); frequency of administration - 2-3 times a day.
Increased calcium excretion (prolonged bed rest, chronic diarrhea, secondary hypocalcemia due to prolonged use of diuretics and antiepileptic drugs, glucocorticoids)
Adults
1000-3000 mg (2-6 tablets) 2-3 times a day.
Children
3-4 years - 1000 mg (2 tablets); 5-6 years - 1000-1500 mg (2-3 tablets); 7-9 years - 1500-2000 mg (3-4 tablets); 10-14 years - 2000-3000 mg (4-6 tablets); frequency of administration - 2-3 times a day.
Poisoning with magnesium salts, oxalic and fluorine acids and their soluble salts
Adults
1000-3000 mg (2-6 tablets) 2-3 times a day.
Children
3-4 years - 1000 mg (2 tablets); 5-6 years - 1000-1500 mg (2-3 tablets); 7-9 years - 1500-2000 mg (3-4 tablets); 10-14 years - 2000-3000 mg (4-6 tablets); frequency of administration - 2-3 times a day.
Hyperkalemic form of paroxysmal myoplegia
Adults
1000-3000 mg (2-6 tablets) 2-3 times a day.
Children
3-4 years - 1000 mg (2 tablets); 5-6 years - 1000-1500 mg (2-3 tablets); 7-9 years - 1500-2000 mg (3-4 tablets); 10-14 years - 2000-3000 mg (4-6 tablets); frequency of administration - 2-3 times a day.
The duration of use for the prevention and treatment of calcium deficiency is determined by the physician and averages from ten days to one and a half months.
If improvement does not occur after treatment, or symptoms worsen, or new symptoms appear, consult a physician. Use the product only according to the indications, method of use, and dosages specified in the product instructions.

Composition per tablet
Active ingredient: calcium gluconate monohydrate - 500.0 mg;
Excipients: potato starch, talc, calcium stearate.

Round, flat-cylindrical white tablets, with a bevel and score line.

• Hypersensitivity to the components of the drug;

• Hypercalcemia (calcium ion concentration should not exceed 12 mg% or 6 mEq/L);

• Severe hypercalciuria;

• Nephrourolithiasis (calcium);

• Severe renal insufficiency;

• Sarcoidosis;

• Simultaneous use of cardiac glycosides (risk of arrhythmias);

• Children under 3 years of age.

With caution
Dehydration, electrolyte disturbances (risk of developing hypercalcemia), diarrhea, malabsorption syndrome, calcium nephrourolithiasis (in history), mild hypercalciuria, moderate chronic renal insufficiency, chronic heart failure, widespread atherosclerosis, hypercoagulation.

Use during pregnancy and breastfeeding
The use of the drug is permissible considering the benefit to the woman/risk to the fetus (child), as determined by the physician. When taking calcium supplements during breastfeeding, it is possible for it to pass into breast milk. Calcium crosses the placental barrier and enters breast milk. The use of the drug during pregnancy and breastfeeding is only possible under strict control of serum calcium concentration, as hypercalcemia can negatively affect the fetus and child.

In patients with mild hypercalciuria, decreased glomerular filtration, or a history of nephrolithiasis, treatment should be conducted under the control of calcium ion concentration in urine.
Patients prone to kidney stone formation are advised to increase their fluid intake.

Effect on the ability to drive vehicles and operate machinery
The use of the drug does not affect the ability to drive vehicles and engage in other potentially dangerous activities that require increased attention and quick psychomotor reactions.

To assess the frequency of adverse events, the following WHO classification is used: very common (> 1/10); common (> 1/100 and < 1/10); uncommon (≥ 1/1000 and 1/10000 and < 1/1000); very rare (< 1/10000); frequency unknown - cannot be determined from available data. Metabolism and nutrition disorders: uncommon - hypercalcemia and hypercalciuria; very rare - milk-alkali syndrome (generally only in cases of overdose). Cardiac disorders: rare - arrhythmias and bradycardia. Gastrointestinal disorders: Rare - mild gastrointestinal disturbances (constipation, diarrhea); very rare - dyspepsia. Skin and subcutaneous tissue disorders: very rare - itching, rash, urticaria. If you experience any side effects listed in the instructions, or if they worsen, or if you notice any other side effects not listed in the instructions, please inform your doctor.Symptoms Hypercalcemia (drowsiness, weakness, anorexia, abdominal pain, vomiting, nausea, constipation, polydipsia, polyuria, increased fatigue, irritability, malaise, depression, dehydration, possible heart rhythm disturbances, myalgia, arthralgia, arterial hypertension). Treatment Discontinuation of the drug; in severe cases - parenteral calcitonin at a dose of 5-10 IU/kg body weight per day (when diluted in 500 ml of sterile 0.9% sodium chloride solution), intravenously by infusion, duration of administration 6 hours. Slow intravenous bolus administration may be possible 2-4 times a day.Pharmaceutically incompatible with carbonates, salicylates, sulfates (forms insoluble or poorly soluble calcium salts). Due to the formation of insoluble complexes, it is incompatible with licorice root preparations and tetracycline antibiotics (reduces antibacterial effect). Reduces the effect of "slow" calcium channel blockers. When used simultaneously with quinidine, there may be a slowing of intraventricular conduction and an increase in quinidine toxicity. Slows the absorption of tetracyclines, digoxin, oral iron preparations (the interval between their administration should be at least 2 hours). In combination with thiazide diuretics, calcium gluconate may enhance hypercalcemia. Reduces the effect of calcitonin in hypercalcemia. Reduces the bioavailability of phenytoin. If you are using the above-mentioned or other medications (including over-the-counter), consult your doctor before using calcium gluconate.

Calcium ions are involved in the formation of bone tissue, the blood coagulation process, and are necessary for maintaining stable cardiac activity and the transmission of nerve impulses. A decrease in the concentration of calcium ions in the blood plasma and tissues can lead to the development of various pathological processes. Hypocalcemia results in impaired function of skeletal and smooth muscles, cardiovascular system dysfunction, disruption of the blood coagulation system, and the development of osteoporosis.

Approximately 1/5 - 1/3 of the orally administered drug is absorbed in the small intestine; this process depends on the presence of vitamin D, pH, dietary characteristics, and the presence of factors that can bind calcium ions. The absorption of calcium ions increases in cases of deficiency and with a diet low in calcium. About 20% is excreted by the kidneys, while the remaining amount (80%) is excreted by the intestines.